APA (7th ed.) Citation

Wellhausen, J., Röhl, L., Berszin, M., Krücken, I., Krücken, I., Zebralla, V., . . . Wichmann, G. Suppression of MCP-1, IFN-γ and IL-6 production of HNSCC ex vivo by pembrolizumab added to docetaxel and cisplatin (TP) exceeding those of TP alone is linked to improved survival. Frontiers Media S.A.

Chicago Style (17th ed.) Citation

Wellhausen, Jana, et al. Suppression of MCP-1, IFN-γ and IL-6 Production of HNSCC Ex Vivo by Pembrolizumab Added to Docetaxel and Cisplatin (TP) Exceeding Those of TP Alone Is Linked to Improved Survival. Frontiers Media S.A.

MLA (9th ed.) Citation

Wellhausen, Jana, et al. Suppression of MCP-1, IFN-γ and IL-6 Production of HNSCC Ex Vivo by Pembrolizumab Added to Docetaxel and Cisplatin (TP) Exceeding Those of TP Alone Is Linked to Improved Survival. Frontiers Media S.A.